Tenders

Drugs with the Active Ingredient Ustekinumab (Atc: L04ac05 - in the Strengths 45 and 90 Mg Per Dosage Unit)

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Substance Filgotinib, Atc L04aa45 for the Period October 15, 2023 - October 31, 2025

Conclusion of a Non-Exclusive Framework Agreement for Investigations and Appraisals in the Open House Procedure of the West Branch

Oh-Biologica-2023-25 ​​- Etanercept

Conclusion of a Non-Exclusive Discount Agreement According to Section 130A Paragraph 8 Sgb V for the Active Substance Testosterone (Exclusively Ilo), Atc G03ba03 for the Period October 1St, 2023 - September 30Th, 2025

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Ingredient Roflumilast (Exclusively with a Potency of 250 Yg), Atc R03dx07 for the Period October 1St, 2023 - September 30Th, 2025

Conclusion of a Non-Exclusive Discount Agreement in Accordance with § 130A Paragraph 8 Sgb V for the Ws Allergen Extract from House Dust Mites (Excluding Dosage Form Sublingual Tablets) for the Period October 1St, 2023 - September 30Th, 2025

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Paragraph 8 Sgb V for the Active Ingredient Colesevelam, Atc C10ac04 for the Period October 1St, 2023 - September 30Th, 2025

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Saso - Security Assessment and System Optimisation (ex-post)